New Ray Medicine International Holding (HKSE:06108) Net Change in Cash : HK$-50.46 Mil (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

New Ray Medicine International Holding's Net Change in Cash for the six months ended in Dec. 2023 was HK$-8.49 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-50.46 Mil.

New Ray Medicine International Holding Net Change in Cash Historical Data

The historical data trend for New Ray Medicine International Holding's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Ray Medicine International Holding Net Change in Cash Chart

New Ray Medicine International Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

-57.43

-22.91

84.40

4.26

-50.46

New Ray Medicine International Holding Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Change in Cash	Get a 7-Day Free Trial															81.48	1.74	2.52	-41.97	-8.49

New Ray Medicine International Holding Net Change in Cash Calculation

New Ray Medicine International Holding's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-45.407	+	-6.013	+	-1.013	+	1.974
	=	-50.46

New Ray Medicine International Holding's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -12.241 + 2.696 + -0.163 + 1.215

= -8.49

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-50.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

New Ray Medicine International Holding Net Change in Cash Related Terms
Thank you for viewing the detailed overview of New Ray Medicine International Holding's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

New Ray Medicine International Holding (HKSE:06108) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » Net Change in Cash

Comparable Companies

HKSE:02211 HKSE:00348 WBA BSP:RADL3 HKSE:00241 TSE:3088 SAU:4164 SHSE:603939 TSE:3349 SHSE:600998 HKSE:09885 TSE:3391 TSE:3141 JSE:CLS TSE:9989 TSE:7649 SAU:4163 SHSE:603883 TSE:3549 SZSE:002727

Traded in Other Exchanges

N/A

Address

19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN

Website

http://www.newraymedicine.com

New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.

Executives

Dai Xiaosong

Eagle Amber Holdings Limited

Chu Xueping 2201 Interest of corporation controlled by you

Qian Shenglei 2101 Beneficial owner

Zhang Jiang 2201 Interest of corporation controlled by you

Yang Fang 2202 Interest of your spouse

Zhou Ling 2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines

Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping	2201 Interest of corporation controlled by you
Qian Shenglei	2101 Beneficial owner
Zhang Jiang	2201 Interest of corporation controlled by you
Yang Fang	2202 Interest of your spouse
Zhou Ling	2101 Beneficial owner